Efficacy, safety and tolerability of rasagiline as adjunctive therapy in elderly patients with Parkinson's disease

European Journal of Neurology

Volumn 19, Issue 2, 2012, Pages 258-264

  Tolosa, E ^a   Stern, M B ^b  

^a HOSPITAL CLÍNIC   (Spain)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Dyskinesia; Elderly; Motor fluctuations; Parkinson's disease; Rasagiline

Indexed keywords

LEVODOPA; PLACEBO; RASAGILINE;

ACCIDENTAL INJURY; ADJUVANT THERAPY; AGED; ARTICLE; CLINICAL GLOBAL IMPROVEMENT; COMPARATIVE STUDY; CONSTIPATION; CONTROLLED STUDY; DEPRESSION; DOPAMINERGIC ACTIVITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; FEMALE; GERIATRIC PATIENT; HALLUCINATION; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; NAUSEA; ORTHOSTATIC HYPOTENSION; PAIN; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCORING SYSTEM; SIDE EFFECT; SOMNOLENCE; UNIFIED PARKINSON DISEASE RATING SCALE; WEIGHT REDUCTION;

ADULT; AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INDANS; MALE; MIDDLE AGED; MONOAMINE OXIDASE INHIBITORS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; TREATMENT OUTCOME;

EID: 84856028448     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2011.03484.x     Document Type: Article

References (26)

1. Finberg JPM, Tenne M, Youdim MBH. Selective irreversible propargyl derivative inhibitors of monoamine oxidase (MAO) without the cheese effect. Youdim MBH, Paykel ES (eds). Monoamine Oxidase Inhibitors - The State of the Art. Chichester: Wiley: 1981: 31-43.
2. Rabey JM, Sagi I, Huberman M, et al. Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: a double-blind study as adjunctive therapy to levodopa. Clin Neuropharmacol 2000; 23: 324-330.
3. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease (the TEMPO study). Arch Neurol 2002; 59: 1937-1943.
4. Olanow CW, Rascol O, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 2009; 361: 1268-1278.
5. Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 2005; 62: 241-248.
6. Rascol O, Brooks DJ, Melamed E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 2005; 365: 947-954.
7. Olanow CW, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease: treatment guidelines. Neurology 1998; 50(Suppl. 3): S1-S57.
8. Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology 2001; 56(Suppl. 5): S1-S88.
9. de Rijk MC, Launer LJ, Berger K, et al., for the Neurologic Diseases in the Elderly Research Group. Prevalence of Parkinson's disease in Europe: a collaborative study of population-based cohorts. Neurology 2000; 11(Suppl. 5): S21-S23.
10. Goetz CG, Schwid SR, Eberly SW, Oakes D, Shoulson I, Parkinson Study Group TEMPO and PRESTO Investigators. Safety of rasagiline in elderly patients with Parkinson disease. Neurology 2006; 66: 1427-1429.
11. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967; 17: 427-442.
12. Hauser RA, Friedlander J, Zesiewicz TA, et al. A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia. Clin Neuropharmacol 2000; 23: 75-81.
13. National Institute for Mental Health. 028 CGI. Clinical Global Impressions. Rockville, MD, USA: US Department of Health, Education, and Welfare, 1976.
14. Fahn S, Elton RL, UPDRS development committee. Unified Parkinson's Disease Rating Scale (UPDRS). Florham Park, New Jersey, USA: Macmillan, 1987.
15. Schwid S, for PRESTO and LARGO Investigators. PRESTO and LARGO: once-daily rasagiline produces consistent treatment benefits in US and European studies of Parkinson's disease patients. Eur J Neurol 2006; 13(Suppl. 2): 95.
16. Parkinson Study Group. Entacapone improves motor fluctuations in levodopa treated Parkinson's disease patients. Ann Neurol 1997; 42: 747-755.
17. Lieberman AN, Ranhosky A, Korts D. Clinical evaluation of pramiprexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology 1997; 49: 162-168.
18. Lieberman AN, Olanow CW, Sethi KD, et al. A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Neurology 1998; 51: 1057-1062.
19. Poewe WH, Rascol O, Quinn N, et al. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol 2007; 6: 513-520.
20. Rajput AH, Martin W, Saint-Hilaire MH, Dorflinger E, Pedder S. Tolcapone improves motor function in parkinsonian patients with the "wearing-off" phenomenon: a double-blind, placebo-controlled, multicenter trial. Neurology 1997; 49: 1066-1071.
21. Waters CH, Kurth M, Bailey P, et al. Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. The Tolcapone Stable Study Group. Neurology 1997; 49: 665-671.
22. Rinne UK, Larsen JP, Siden A, Worm-Petersen J, Nomecomt Study Group. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Neurology 1998; 51: 1309-1314.
23. Shulman LM, Minagar A, Rabinstein A, Weiner WJ. The use of dopamine agonists in very elderly patients with Parkinson's disease. Mov Disord 2000; 15: 664-668.
24. Pahwa R, Factor SA, Lyons KE, et al. Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006; 66: 983-995.
25. Horstink M, Tolosa E, Bonuccelli U, et al. Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson's disease. Eur J Neurol 2006; 13: 1186-1202.
26. Waters CH, Sethi KD, Hauser RA, et al., Zydis Selegiline Study Group Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study. Mov Disord 2004; 19: 426-432.